Follow-up of a hip replacement stem for people with joint disease
Checks safety and how well a hip implant stem works over time.
Key facts
- Who runs it
- MicroPort Orthopedics Inc.
- Where
- Englewood and Scottsdale, United StatesSee the 2 sites
- Trial code
- Registry title
- Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem
- Status
- Enrolling by invitation
- People taking part
- 150 people, planned
- Started
- 21 Oct 2020
- Expected to end
- 1 Nov 2033
- Type of study
- Observational
- Treatments tested
- Total Hip Arthroplasty Implant
- Record updated
- 20 March 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have had, or will have, a first total hip replacement (THA) using the PROFEMUR® Preserve Classic Stem with other WMT or MPO hip parts. It follows them for 10 years.
- Age
- 21 years and older
- Sex
- All sexes
- Disease stage
- First (primary) hip replacement for non-inflammatory joint wear such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli or painful hip dysplasia. Also for inflammatory joint disease such as rheumatoid arthritis, or to correct a functional deformity.
- Earlier treatment
- People who already have the implant must join within 3 years of their first hip replacement. People who had a revision surgery after other treatments or devices failed cannot join.
Main reasons for not taking part
- Hip parts from makers other than MPO or WMT
- Infection at the time of implant, in the hip or elsewhere in the body
- Hepatitis or HIV infection, now or in the past
- Nerve, muscle or bone problems that affect walking or weight-bearing, or neuropathic joints
- Documented substance abuse, or being in prison now or soon
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Has previously undergone or currently has determined to undergo primary THA with the specified combination of components: PROFEMUR® Preserve Classic Stem combined with other Wright Medical Technologies (WMT) or MPO THA components including acetabular shells, acetabular liners and femoral heads
- Has previously undergone or currently has been determined to undergo a primary THA for any of the following:
- non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia
- inflammatory degenerative joint disease such as rheumatoid arthritis
- correction of functional deformity 3. Willing and able to complete required study visits and assessments through the 10 year postoperative follow-up visit 4. Previously implanted subjects must be enrolled within 3 years of their primary THA implantation
Who cannot take part
- Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
- Has or had an overt infection at the time of implantation
- Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation
- Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation
- Has or had hepatitis or HIV infection
- Has or had a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing
- Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
- Has a medical condition, as judged by the investigator, that would interfere with the subject's ability to comply with the requirements of the protocol -
- Skeletally immature (less than 21 years of age) at time of implantation
- Implanted with non-MPO or non-WMT components (femoral heads, acetabular shells, acetabular liners)
- Has or had neuropathic joints
- Has had a revision procedure(s) where other treatments or devices have failed; and treatment of fractures that are unmanageable using other techniques
- Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
- Unwilling or unable to sign the Informed Consent document
- Has documented substance abuse issue
- Currently incarcerated or has impending incarceration
Where in United States
- HCA Research Institute, OrthoONE at Swedish Medical CenterEnglewood, United StatesEnrolling by invitation
- HonorHealth Research InstituteScottsdale, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Sponsor is conducting this post market clinical study to evaluate the safety and effectiveness of its PROFEMUR® Preserve Classic Femoral Stem. This type of study is required by regulatory authorities for all devices that have been approved in Europe (EU) to evaluate the medium and long-term clinical evidence. This study has been designed in accordance with MEDDEV2.12/2 (European Medical Device Vigilance System) rev2 and ISO (International Organization of Standardization) 14155:2011 guidelines.
Treatments tested
- Total Hip Arthroplasty Implant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem
- Plain-language title
- Follow-up of a hip replacement stem for people with joint diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 March 2024